SG11202011891YA - Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications - Google Patents
Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indicationsInfo
- Publication number
- SG11202011891YA SG11202011891YA SG11202011891YA SG11202011891YA SG11202011891YA SG 11202011891Y A SG11202011891Y A SG 11202011891YA SG 11202011891Y A SG11202011891Y A SG 11202011891YA SG 11202011891Y A SG11202011891Y A SG 11202011891YA SG 11202011891Y A SG11202011891Y A SG 11202011891YA
- Authority
- SG
- Singapore
- Prior art keywords
- htp
- formulations
- various indications
- better bioavailability
- hydroxy tryptophan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862686774P | 2018-06-19 | 2018-06-19 | |
| PCT/US2019/037349 WO2019245925A1 (en) | 2018-06-19 | 2019-06-14 | Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202011891YA true SG11202011891YA (en) | 2021-01-28 |
Family
ID=68984346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202011891YA SG11202011891YA (en) | 2018-06-19 | 2019-06-14 | Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210361566A1 (en) |
| EP (1) | EP3810111A4 (en) |
| JP (1) | JP2021529158A (en) |
| KR (1) | KR20210031910A (en) |
| CN (1) | CN112469400A (en) |
| AU (1) | AU2019289132A1 (en) |
| BR (1) | BR112020026266A2 (en) |
| CA (1) | CA3103477A1 (en) |
| IL (1) | IL279509A (en) |
| MX (1) | MX2020013654A (en) |
| SG (1) | SG11202011891YA (en) |
| WO (1) | WO2019245925A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022320730A1 (en) * | 2021-07-30 | 2024-03-14 | Evecxia Therapeutics, Inc. | 5-hydroxytryptophan gastroretentive dosage forms |
| US11779567B2 (en) | 2021-10-14 | 2023-10-10 | Evecxia Therapeutics, Inc. | Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes |
| CN114569607B (en) * | 2022-02-28 | 2024-02-13 | 军事科学院军事医学研究院环境医学与作业医学研究所 | Application of 5-hydroxytryptophan in preparation of health care product or medicine for improving female physiological cycle disorder caused by altitude hypoxia |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4140755A (en) | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
| DE69831335T3 (en) | 1997-06-06 | 2015-01-15 | Depomed, Inc. | MAGNIFYING ORAL DOSAGE FORMS OF WATER-SOLUBLE MEDICAMENTS WITH CONTROLLED RELEASE |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| IN186245B (en) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
| CA2320900C (en) | 1998-03-19 | 2009-10-27 | Bristol-Myers Squibb Company | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| MXPA03012041A (en) * | 2001-07-04 | 2004-03-26 | Sun Pharmaceutical Ind Ltd | Gastric retention controlled drug delivery system. |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US7094427B2 (en) | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| EP2255795A1 (en) * | 2002-09-28 | 2010-12-01 | McNeil-PPC, Inc. | Immediate release dosage form comprising shell having openings therein |
| ITMI20041689A1 (en) | 2004-09-01 | 2004-12-02 | Bojidar Mihaylov Stankov | NEW FORMULATIONS OF CONTROLLED RELEASE CONTAINING 5-HYDROXYTYRIPHOPHANE AND TRIPTOPHAN |
| WO2007069358A1 (en) * | 2005-12-14 | 2007-06-21 | Kissei Pharmaceutical Co., Ltd. | Novel preparation of gastric retention type |
| KR20080076382A (en) | 2007-02-15 | 2008-08-20 | (주)아모레퍼시픽 | Controlled-release preparation containing cilostazol and process for the preparation thereof |
| EP1980743B1 (en) | 2007-04-10 | 2015-09-09 | Nissan Motor Co., Ltd. | Fuel pump driving device |
| WO2009043834A1 (en) | 2007-10-01 | 2009-04-09 | Neurosearch A/S | Pharmaceutical compositions of 5-hydr0xytrypt0phan and serotonin-enhancing compound |
| HUE030958T2 (en) | 2008-04-18 | 2017-06-28 | Intec Pharma Ltd | Gastroretentive drug delivery for carbidopa/levodopa |
| ZA200903854B (en) * | 2008-06-19 | 2011-02-23 | Univ Of The Witwatesrand Johannesburg | A gastroretentive pharmaceutical dosage form |
| US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| BRPI0917444A2 (en) | 2008-08-15 | 2015-12-01 | Depomed Inc | gastric retention pharmaceutical compositions for the treatment and prevention of snc diseases |
| EP2629615B1 (en) * | 2010-10-22 | 2018-10-10 | Duke University | Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies |
| ES2586057T3 (en) * | 2011-07-26 | 2016-10-11 | Yuhan Corporation | Sustained release tablet comprising pregabalin through a two phase release control system |
| US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
| AU2016342374B2 (en) | 2015-10-23 | 2022-08-04 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained release of therapeutic agents and methods of use thereof |
-
2019
- 2019-06-14 MX MX2020013654A patent/MX2020013654A/en unknown
- 2019-06-14 EP EP19823684.6A patent/EP3810111A4/en not_active Withdrawn
- 2019-06-14 BR BR112020026266-8A patent/BR112020026266A2/en not_active Application Discontinuation
- 2019-06-14 CN CN201980041490.0A patent/CN112469400A/en active Pending
- 2019-06-14 CA CA3103477A patent/CA3103477A1/en active Pending
- 2019-06-14 WO PCT/US2019/037349 patent/WO2019245925A1/en unknown
- 2019-06-14 AU AU2019289132A patent/AU2019289132A1/en not_active Abandoned
- 2019-06-14 SG SG11202011891YA patent/SG11202011891YA/en unknown
- 2019-06-14 JP JP2020569953A patent/JP2021529158A/en active Pending
- 2019-06-14 US US17/252,961 patent/US20210361566A1/en not_active Abandoned
- 2019-06-14 KR KR1020217001446A patent/KR20210031910A/en unknown
-
2020
- 2020-12-16 IL IL279509A patent/IL279509A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210361566A1 (en) | 2021-11-25 |
| MX2020013654A (en) | 2021-03-25 |
| CA3103477A1 (en) | 2019-12-26 |
| IL279509A (en) | 2021-01-31 |
| CN112469400A (en) | 2021-03-09 |
| EP3810111A1 (en) | 2021-04-28 |
| KR20210031910A (en) | 2021-03-23 |
| BR112020026266A2 (en) | 2021-03-30 |
| JP2021529158A (en) | 2021-10-28 |
| EP3810111A4 (en) | 2022-03-23 |
| WO2019245925A1 (en) | 2019-12-26 |
| AU2019289132A1 (en) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279509A (en) | Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications | |
| IL260263A (en) | Use of tryptophan derivatives for protein formulations | |
| EP3612179A4 (en) | Apparatus for preparation of pharmacologically-relevant compounds from botanical sources | |
| DK3653617T3 (en) | PROCEDURE FOR THE PREPARATION OF (S) -NICOTIN FROM MYOSMIN | |
| HK1257058A1 (en) | Apparatus for cable routing | |
| EP3713410A4 (en) | Apparatus for perfusion of an excised organ | |
| SG11202006080SA (en) | Liquid oral formulations for pde v inhibitors | |
| DK3240308T3 (en) | MICROPHONE CALIBRATION COMPENSATION FROM CABLE TRANSFER FUNCTION | |
| ZA202102263B (en) | Oral formulations of kappa opioid receptor agonists | |
| IL282773A (en) | Edaravone suspension for oral administration | |
| IL259952A (en) | Use of tryptophan derivatives for protein formulations | |
| EP3661451C0 (en) | Support for medical instruments | |
| EP3845856A4 (en) | Apparatus for measuring telescoping of coil | |
| EP3694558A4 (en) | Il-4-fusion formulations for treatment of central nervous system (cns) tumors | |
| IL258832A (en) | Head support for wheelchair | |
| SG11202105336TA (en) | Pharmaceutical formulations of cyclosporine analogs | |
| EP3759227A4 (en) | Improved method for the synthesis of tryptophan analogs in aqueous solvents at reduced temperatures | |
| IL283593A (en) | Oral formulations of branaplam | |
| GB201809050D0 (en) | Modulators of tryptophan catabolism | |
| SG11202111350RA (en) | Formulations of psma imaging agents | |
| EP3532811A4 (en) | Apparatus for supporting musical instruments | |
| GB201710241D0 (en) | New route of synthesis for opicapone | |
| EP3909329C0 (en) | Signaling of reception-to-transmission measurements for round-trip-time (rtt)-based positioning | |
| IT201700090801A1 (en) | Support tripod for photographic equipment | |
| EP3632345A4 (en) | Apparatus for fixing instrument within intestinal canal |